Restructured Melinta now wants to buy fellow antibiotic maker Tetraphase; TA Associates mulls $500M deal for a stake in CDMO
→ Yet another buyer has emerged in what is shaping up to be a bidding war for Tetraphase and its marketed antibiotic. Melinta — a fellow antibiotics maker that’s freshly restructured under Chapter 11 and now privately owned by Deerfield — is offering to buy it all for $27 million, more than double the original offer by AcelRx that the Tetraphase board had recommended back in March. Since then, La Jolla has also proposed a $22 million deal.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters